How does GLP-1 use impact psychological wellbeing in adults with diabetes and obesity? A recent study published in JAMA Psychiatry sought to understand this relationship. The connection between depression and diabetes/obesity is well-established and goes both ways; individuals with diabetes are more likely to report feeling depressed, and individuals with depression are more likely to develop obesity. GLP-1s agonists, which are highly effective in treating obesity and type 2 diabetes, have exploded in popularity in recent years, making it imperative to understand how GLP-1 use affects mental health.
This study addresses the question by conducting a meta-analysis of 80 rigorous scientific papers examining the relationship between GLP-1 use and a range of wellbeing indicators in individuals with no known psychiatric condition, and found that, on the whole, GLP-1s had a moderately positive impact on mental health. Specifically, the authors found that GLP-1 use did not increase symptoms like anxiety, insomnia, suicidality, or depression, and that individuals using GLP-1s reported modest improvements across a range of quality-of-life measures.
These findings are encouraging, as they demonstrate the psychiatric safety of using GLP-1 drugs to treat obesity and type 2 diabetes. However, further research is needed to fully understand the relationship between GLP-1s and mental health, especially among individuals with known psychiatric conditions.
Read the full article: www.psychiatrictimes.com/view/evaluating-glucagon-like-peptide-1-receptor-agonists-and-mental-health-outcomes